France · Delayed Price · Currency is EUR Neurones Statistics
Total Valuation
Neurones has a market cap or net worth of EUR 893.16 million. The enterprise value is 664.18 million.
| Market Cap | 893.16M |
| Enterprise Value | 664.18M |
Important Dates
The next estimated earnings date is Tuesday, May 19, 2026.
| Earnings Date | May 19, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Neurones has 23.95 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | 23.95M |
| Shares Outstanding | 23.95M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 4.48% |
| Owned by Institutions (%) | 7.12% |
| Float | 11.70M |
Valuation Ratios
The trailing PE ratio is 17.43 and the forward PE ratio is 16.02.
| PE Ratio | 17.43 |
| Forward PE | 16.02 |
| PS Ratio | 1.04 |
| PB Ratio | 1.92 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | 14.68 |
| P/OCF Ratio | 12.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.98, with an EV/FCF ratio of 10.92.
| EV / Earnings | 12.75 |
| EV / Sales | 0.77 |
| EV / EBITDA | 6.98 |
| EV / EBIT | 8.79 |
| EV / FCF | 10.92 |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.43 |
| Quick Ratio | 2.36 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.49 |
| Debt / FCF | 0.77 |
| Interest Coverage | 42.87 |
Financial Efficiency
Return on equity (ROE) is 13.73% and return on invested capital (ROIC) is 32.14%.
| Return on Equity (ROE) | 13.73% |
| Return on Assets (ROA) | 6.41% |
| Return on Invested Capital (ROIC) | 32.14% |
| Return on Capital Employed (ROCE) | 15.15% |
| Weighted Average Cost of Capital (WACC) | 6.39% |
| Revenue Per Employee | 119,251 |
| Profits Per Employee | 7,244 |
| Employee Count | 7,208 |
| Asset Turnover | 1.16 |
| Inventory Turnover | 3,079.37 |
Taxes
In the past 12 months, Neurones has paid 23.22 million in taxes.
| Income Tax | 23.22M |
| Effective Tax Rate | 27.29% |
Stock Price Statistics
The stock price has decreased by -21.22% in the last 52 weeks. The beta is 0.42, so Neurones's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -21.22% |
| 50-Day Moving Average | 35.79 |
| 200-Day Moving Average | 39.45 |
| Relative Strength Index (RSI) | 55.87 |
| Average Volume (20 Days) | 15,884 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neurones had revenue of EUR 857.18 million and earned 52.07 million in profits. Earnings per share was 2.14.
| Revenue | 857.18M |
| Gross Profit | 418.37M |
| Operating Income | 75.58M |
| Pretax Income | 85.07M |
| Net Income | 52.07M |
| EBITDA | 87.03M |
| EBIT | 75.58M |
| Earnings Per Share (EPS) | 2.14 |
Balance Sheet
The company has 340.78 million in cash and 46.92 million in debt, with a net cash position of 293.86 million or 12.27 per share.
| Cash & Cash Equivalents | 340.78M |
| Total Debt | 46.92M |
| Net Cash | 293.86M |
| Net Cash Per Share | 12.27 |
| Equity (Book Value) | 464.87M |
| Book Value Per Share | 16.45 |
| Working Capital | 358.47M |
Cash Flow
In the last 12 months, operating cash flow was 71.28 million and capital expenditures -10.44 million, giving a free cash flow of 60.84 million.
| Operating Cash Flow | 71.28M |
| Capital Expenditures | -10.44M |
| Depreciation & Amortization | 11.45M |
| Net Borrowing | -11.23M |
| Free Cash Flow | 60.84M |
| FCF Per Share | 2.54 |
Margins
Gross margin is 48.81%, with operating and profit margins of 8.82% and 6.07%.
| Gross Margin | 48.81% |
| Operating Margin | 8.82% |
| Pretax Margin | 9.92% |
| Profit Margin | 6.07% |
| EBITDA Margin | 10.15% |
| EBIT Margin | 8.82% |
| FCF Margin | 7.10% |
Dividends & Yields
This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 3.75%.
| Dividend Per Share | 1.40 |
| Dividend Yield | 3.75% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 60.73% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 3.67% |
| Earnings Yield | 5.83% |
| FCF Yield | 6.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neurones has an Altman Z-Score of 4.42 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.42 |
| Piotroski F-Score | 7 |